STOCK TITAN

MARIZYME INC - MRZM STOCK NEWS

Welcome to our dedicated page for MARIZYME news (Ticker: MRZM), a resource for investors and traders seeking the latest updates and insights on MARIZYME stock.

Marizyme, Inc., a biotechnology company focused on life sciences, aims to develop therapies addressing acute care needs. Formerly known as GBS Enterprises, the company focuses on commercializing products like DuraGraft™ for CABG surgeries. With a recent FDA de novo clearance for DuraGraft™, Marizyme is set to revolutionize cardiac care.

Rhea-AI Summary
Marizyme partners with Qualigen Therapeutics to commercialize FDA-cleared DuraGraft™ for CABG surgeries, with Qualigen providing funding and a share of future profits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
66.67%
Tags
none
-
News
Rhea-AI Summary
Marizyme, Inc. provides a business update on FDA clearance for DuraGraft™ and outlines its business priorities for 2024. The company has secured FDA clearance for DuraGraft™, a vascular conduit solution for CABG surgeries. They plan to penetrate the U.S. market, drive sales in Europe and Asia, reduce expenses, and expand their intellectual property portfolio.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
none
-
Rhea-AI Summary
The Watchlist by The Market Herald releases new interviews with FPX Nickel, Pelangio Exploration, Nicola Mining, and Max Resource
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.24%
Tags
none
Rhea-AI Summary
Marizyme receives FDA clearance for DuraGraft, the first and only medical device for use in CABG surgeries
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
50%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.69%
Tags
none
Rhea-AI Summary

Marizyme (OTCQB: MRZM) announced that the USPTO has granted a Notice of Allowance for its patent application related to DuraGraft, a solution enhancing organ and tissue preservation during surgeries. This patent, covering a stable solution kit, is significant for the company's flagship product, currently approved in Europe and seeking FDA approval in the U.S. CEO David Barthel emphasized that the allowance strengthens their patent estate and protects commercial opportunities in the U.S., reflecting a crucial milestone for Marizyme.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Marizyme Inc. (OTCQB:MRZM) has successfully closed its acquisition of My Health Logic Inc., a subsidiary of Health Logic Interactive Inc. This acquisition enhances Marizyme's product pipeline with My Health Logic's lab-on-chip technology and MATLOC 1 device, aimed at improving chronic kidney disease (CKD) diagnostics. Concurrently, a private placement of $6 million was completed to support business development. The company is also positioned for an anticipated public offering and Nasdaq uplisting in 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.73%
Tags
-
Rhea-AI Summary

Marizyme Inc. (MRZM) announced the results of the GOAL Study at the 7th Annual International Coronary Congress. Conducted by Dr. Bernhard Winkler, this study evaluated DuraGraft® Vascular Conduit Solution versus standard care during CABG surgeries. Results showed significant reductions in perioperative high-sensitivity Troponin-I levels in patients using DuraGraft, suggesting enhanced myocardial protection. These findings validate earlier research and highlight DuraGraft's potential in cardiac surgery, paving the way for more extensive investigations into its long-term benefits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary

Marizyme Inc. (MRZM) has received notice for the allowance of foundational patent applications in key markets for its core technologies. This includes patent protections for its flagship product, DuraGraft®, in Brazil, China, and Malaysia, enhancing its commercial potential. DuraGraft® is designed to improve outcomes in vascular surgeries by preserving grafts during procedures. Additionally, a patent related to its Krillase enzyme technology has been allowed in Europe, expanding its therapeutic applications. The company has partnered with Dentons US LLP to manage its global patent portfolio.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none

FAQ

What is the current stock price of MARIZYME (MRZM)?

The current stock price of MARIZYME (MRZM) is $0.036 as of October 9, 2024.

What is the market cap of MARIZYME (MRZM)?

The market cap of MARIZYME (MRZM) is approximately 4.0M.

What is Marizyme, Inc. focused on?

Marizyme, Inc. is a biotechnology company dedicated to developing therapies that address critical needs in the acute care space.

What is the flagship product of Marizyme, Inc.?

The flagship product of Marizyme, Inc. is DuraGraft™, a solution indicated for adult patients undergoing CABG surgeries for the flushing and storage of saphenous vein grafts.

What recent achievement has Marizyme, Inc. accomplished?

Marizyme, Inc. received a de novo clearance from the FDA for DuraGraft™, making it the first and only FDA cleared medical device for use during CABG surgeries.

What is the potential impact of DuraGraft™ in cardiac care?

DuraGraft™ has the potential to change the landscape of cardiac care by reducing long-term mortality and maintaining the structural integrity of vascular conduits.

What is Marizyme, Inc.'s mission?

Marizyme, Inc. aims to present breakthrough solutions to cardiac surgeons and their CABG patients, with a focus on transforming cardiac care.

MARIZYME INC

OTC:MRZM

MRZM Rankings

MRZM Stock Data

3.95M
85.72M
34.96%
Biotechnology
Healthcare
Link
United States of America
Jupiter